Recent Analysts’ Ratings Changes for Heron Therapeutics (HRTX)

Several brokerages have updated their recommendations and price targets on shares of Heron Therapeutics (NASDAQ: HRTX) in the last few weeks:

• 12/19/2024 – Heron Therapeutics was downgraded by analysts at StockNews.com from a “buy” rating to a “hold” rating.
• 12/11/2024 – Heron Therapeutics was upgraded by analysts at StockNews.com from a “hold” rating to a “buy” rating.
• 12/4/2024 – Heron Therapeutics had its “buy” rating reaffirmed by analysts at Needham & Company LLC. They now have a $4.00 price target on the stock.
• 12/3/2024 – Heron Therapeutics was downgraded by analysts at StockNews.com from a “buy” rating to a “hold” rating.
• 11/21/2024 – Heron Therapeutics was downgraded by analysts at StockNews.com from a “buy” rating to a “hold” rating.
• 11/13/2024 – Heron Therapeutics was upgraded by analysts at StockNews.com from a “hold” rating to a “buy” rating.
• 11/13/2024 – Heron Therapeutics had its price target lowered by analysts at Needham & Company LLC from $5.00 to $4.00. They now have a “buy” rating on the stock.

Heron Therapeutics Price Performance

Shares of NASDAQ:HRTX traded up $0.02 during trading on Monday, reaching $1.60. 1,490,615 shares of the stock were exchanged, compared to its average volume of 2,707,370. The firm has a market cap of $243.35 million, a price-to-earnings ratio of -8.89 and a beta of 1.68. The stock has a fifty day moving average of $1.56 and a two-hundred day moving average of $2.19. Heron Therapeutics, Inc. has a 1-year low of $1.04 and a 1-year high of $3.93.

Heron Therapeutics (NASDAQ:HRTX) last released its earnings results on Tuesday, November 12th. The biotechnology company reported ($0.03) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.03). The company had revenue of $32.81 million during the quarter, compared to analysts’ expectations of $36.40 million. During the same quarter in the previous year, the firm earned ($0.17) earnings per share. Sell-side analysts forecast that Heron Therapeutics, Inc. will post -0.13 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in HRTX. Marshall Wace LLP grew its holdings in shares of Heron Therapeutics by 256.2% during the 2nd quarter. Marshall Wace LLP now owns 1,761,051 shares of the biotechnology company’s stock worth $6,164,000 after acquiring an additional 1,266,697 shares during the period. Clearline Capital LP grew its stake in Heron Therapeutics by 48.9% in the third quarter. Clearline Capital LP now owns 2,226,512 shares of the biotechnology company’s stock worth $4,431,000 after purchasing an additional 731,246 shares during the period. AQR Capital Management LLC raised its holdings in Heron Therapeutics by 1,460.9% in the second quarter. AQR Capital Management LLC now owns 607,135 shares of the biotechnology company’s stock worth $2,125,000 after purchasing an additional 568,238 shares in the last quarter. Congress Park Capital LLC lifted its position in Heron Therapeutics by 25.3% during the third quarter. Congress Park Capital LLC now owns 1,978,078 shares of the biotechnology company’s stock valued at $3,936,000 after buying an additional 399,577 shares during the period. Finally, Squarepoint Ops LLC grew its position in shares of Heron Therapeutics by 369.0% in the 2nd quarter. Squarepoint Ops LLC now owns 363,700 shares of the biotechnology company’s stock worth $1,273,000 after buying an additional 286,160 shares during the period. 80.01% of the stock is owned by hedge funds and other institutional investors.

Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.